Vontobel Financial Products GmbH Stock

Certificat

DE000VU655V7

Market Closed - Deutsche Boerse AG 13:50:33 2024-05-31 EDT
77.63 EUR +0.88% Intraday chart for Vontobel Financial Products GmbH
1 month+3.08%
3 months-1.11%
Date Price Change
24-05-31 77.63 +0.88%
24-05-30 76.95 -0.70%
24-05-29 77.49 +0.71%
24-05-28 76.94 -0.88%
24-05-27 77.62 -0.10%

Delayed Quote Deutsche Boerse AG

Last update May 31, 2024 at 01:50 pm

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VU655V
ISINDE000VU655V7
Date issued 2023-05-10
Strike 300 CHF
Maturity 2024-06-21 (20 Days)
Parity 0.3 : 1
Emission price 100
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 103.1
Lowest since issue 72.95

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231 CHF
Average target price
277.5 CHF
Spread / Average Target
+20.14%
Consensus